Citations

Showing 10 of 108152 citations.

Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report
Jiang, Guoqian , Dhruva, Sanket S. , Chen, Jiajing , Doshi, Amit, Zhang, Shumin , Young, H. P. , Ervin, Keondae, Shah, Nilay D. , Patrick Young, H , Drozda, Joseph P. , Schulz, Wade L. , Noseworthy, Peter A. , Yu, Yue , Brandt, Eric, Ross, Joseph S. , COPLAN, PAUL M.

Mayo Clinic

Journal of the American Medical Informatics Association | May 29, 2021 | Volume: 28 | Issue: 10 | Pages: 2241-2250

10.1093/jamia/ocab117 | PMID 34313748 Get It

Abstract Objective The study sought to conduct an informatics analysis on the National Evaluation System for Health Technology Coordinating Center test case of cardiac ablation catheters and to demonstrate the role of informatics approaches in the feasibility assessment of capturing real-world data using unique device identifiers (UDIs) that are fit for purpose for label extensions for 2 cardiac ablation catheters from the electronic health records and other health information technology systems in a multicenter evaluation. Materials and Methods We focused on data capture and transformation and data quality maturity model specified in the National Evaluation System for Health Technology Coordinating Center data quality framework. The informatics analysis included 4 elements: the use of UDIs for identifying device exposure data, the use of standardized codes for defining computable phenotypes, the use of natural language processing for capturing unstructured data elements from clinical data systems, and the use of common data models for standardizing data collection and analyses. Results We found that, with the UDI implementation at 3 health systems, the target device exposure data could be effectively identified, particularly for brand-specific devices. Computable phenotypes for study outcomes could be defined using codes; however, ablation registries, natural language processing tools, and chart reviews were required for validating data quality of the phenotypes. The common data model implementation status varied across sites. The maturity level of the key informatics technologies was highly aligned with the data quality maturity model. Conclusions We demonstrated that the informatics approaches can be feasibly used to capture safety and effectiveness outcomes in real-world data for use in medical device studies supporting label extensions.
The Use of Biologics for the Treatment of Esophageal Crohn Disease
Lui, Jacob , Ramos, Guilherme Piovezani , Codipilly, Don C. , Katzka, David A. , Raffals, Laura E. , Codipilly, Don Chamil , Katzka, David, Ramos, Guilherme P

Mayo Clinic

Inflammatory Bowel Diseases | May 29, 2021 | Volume: 27 | Issue: 9 | Pages: 1544-1547

10.1093/ibd/izab070 | PMID 34050661 Get It

Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis
Chandan, Saurabh , Khan, Shahab R. , Chandan, Ojasvini Choudhry , Kassab, Lena L., Ponnada, Suresh, Kochhar, Gursimran , Chandan, Saurabh , Mohan, Babu P. , Kumar, Anand

Mayo Clinic

Journal of Clinical Gastroenterology | May 29, 2021 | Volume: 55 | Issue: 6 | Pages: 481-491

10.1097/mcg.0000000000001550 | PMID 34049383 Get It

Background: Pouchitis is the most common long-term complication after ileal pouch-anal anastomosis in patients with ulcerative colitis. Those with ≥3 episodes of pouchitis/year and symptoms despite antibiotics are considered to have chronic antibiotic refractory pouchitis (CARP). While several agents including probiotics, steroids and immunomodulators have been used, treatment of CARP remains challenging. We conducted a systematic review and meta-analysis evaluating the safety and efficacy of various biological agents in treatment of CARP. Methods: Multiple databases were searched through June 2020 for studies that reported the efficacy and safety of biological therapy including antitumor necrosis factor-alpha agents [infliximab (IFX) and adalimumab (ADA)], vedolizumab (VDZ), and ustekinumab in CARP. We excluded studies on Crohn’s like and/or other inflammatory complications of the pouch. Meta-analysis was performed to calculate pooled rates of clinical as well as endoscopic improvement and remission. Results: We included 15 studies with 311 patients in our final analysis. Ninety-two patients were treated with IFX, 42 with ADA, 144 with VDZ and 33 with ustekinumab. Pooled rate of clinical improvement was 71.4%, 58.2%, 47.9% and clinical remission was 65.7%, 31%, 47.4% with IFX, ADA, and VDZ, respectively. Pooled rate of endoscopic improvement was achieved in 61.2% patients treated with VDZ while endoscopic remission was achieved in 70.3% patients treated with IFX. Adverse events were reported in 3.9% patients. Conclusion: Biologic therapy is safe and effective in the treatment of CARP.
Call to Pharmacists: End Use of “Red Man Syndrome”
Rivera, Christina G. , Rivera, Christina G , Ryan, Keenan

Mayo Clinic

Annals of Pharmacotherapy | May 29, 2021 | Volume: 56 | Issue: 1 | Pages: 102-103

10.1177/10600280211021417 | PMID 34049456 Get It

Red Man Syndrome is a term used for an adverse event attributed to vancomycin infusion. Based on the presentation within white patients, the term is imprecise at best and can lead to suboptimal classification and management. Recent calls have advocated for the discontinuation of the use of this terminology. Pharmacists should take the lead in advocating for this change.
Optimal Hemodynamics and Risk of Severe Outcomes Post-Left Ventricular Assist Device Implantation
Rosenbaum, Andrew , Ternus, Bradley W., Stulak, John M., Clavell, Alfredo L., Schettle, Sarah D., Behfar, Atta , Jentzer, Jacob C., Rosenbaum, Andrew N , Behfar, Atta , Ternus, Bradley W., Stulak, John M., Clavell, Alfredo L., Schettle, Sarah D., Jentzer, Jacob C.

Mayo Clinic

ASAIO Journal | May 29, 2021 | Volume: 68 | Issue: 3 | Pages: 325-332

10.1097/mat.0000000000001465 | PMID 35213881 Get It

Data on pre-implant hemodynamic optimization before continuous flow left ventricular assist device placement (CF-LVAD) with respect to patient-centered outcomes remain limited. Consecutive patients undergoing CF-LVAD implant between 2007 and 2017 were identified. Hemodynamic variables, trends, and laboratory studies were evaluated pre-LVAD implant in a logistic regression model to identify predictors of the primary composite endpoint: the need for right ventricular assist device therapy, the requirement for hemodialysis at 90 days, and 30-day mortality. Multivariate modeling identified three variables significantly associated with the primary endpoint: right ventricular stroke work index (RVSWI), right atrial pressure (RAP), and blood urea nitrogen (BUN); all immediately pre-LVAD, p < 0.01. Optimal dichotomization points were 500 mmHg*ml*m−2, 12 mmHg, and 40 mg/dL. The three-component model identified an AUC of 0.77 (p < 0.0001) for the composite endpoint. Optimization of 2/3 parameters, 1/3, and 0/3 was associated with odds ratios of 3.5 (95% CI, 1.1−11.7), 7.2 (95% CI, 2.1−24.2), and 20.6 (95% CI, 5.3−80.6), respectively, relative to those patients who were fully optimized (3/3 parameters). The number of optimized parameters was also associated with 1-year overall survival (p = 0.02). Low RVSWI, high RAP, and high BUN were independently associated with adverse outcomes after the CF-LVAD implant, demonstrating a stepwise association with severe postimplant adverse events.
Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis
Yetmar, Zachary A. , Chesdachai, Supavit , Kashour, Tarek , Gerberi, Dana , Badley, Andrew D. , Berbari, Elie F. , Tleyjeh, Imad M. , Gerberi, Danielle J , Badley, Andrew D , Berbari, Elie F , Tleyjeh, Imad M , Yetmar, Zachary A , Chesdachai, Supavit , Riaz, Muhammad

Mayo Clinic

Open Forum Infectious Diseases | May 29, 2021 | Volume: 8 | Issue: 7 | Pages: No page available

10.1093/ofid/ofab284 | PMID 34258316 Get It

Abstract Background Statins up-regulate angiotensin-converting enzyme 2, the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while also exhibiting pleiotropic antiviral, antithrombotic, and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statin use and outcomes of patients with coronavirus disease 2019 (COVID-19). Methods We searched Ovid Medline, Web of Science, Scopus, and the preprint server medRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted relative risk (aRRs) of the association between prior statin use and outcomes of patients with COVID-19 using the DerSimonian-Laird random-effects model and assessed heterogeneity using the I2 index. Results Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395 513 patients. Sixteen of 19 studies had low or moderate risk of bias. Among 109 080 patients enrolled in 13 separate studies, prior statin use was associated with a lower risk of mortality (pooled aRR, 0.65 [95% confidence interval {CI}, .56–.77], I2 = 84.1%) and a reduced risk of severe COVID-19 was also observed in 48 110 patients enrolled in 9 studies (pooled aRR, 0.73 [95% CI, .57–.94], I2 = 82.8%), with no evidence of publication bias. Conclusions Cumulative evidence suggests that prior statin use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.
All‐Cause Failure Rates Increase With Time Following Meniscal Repair Despite Favorable Outcomes: A Systematic Review and Meta‐analysis
Ow, Zachariah Gene Wing , Law, Michelle Shi Ni , Krych, Aaron J. , Saris, Daniël B.F. , Wong, Keng Lin , Lin, Heng An , Krych, Aaron J , Ng, Cheng Han , Debieux, Pedro

Mayo Clinic

Arthroscopy | May 28, 2021 | Volume: 37 | Issue: 12 | Pages: 3518-3528

10.1016/j.arthro.2021.05.033 | PMID 34058318 Get It

Purpose The purpose of this review is to perform a meta‐analysis of studies reporting meniscus repair outcomes. Pooled analyses of such studies will provide an accurate estimate of the outcomes that can be expected following meniscal repair at various postoperative time points. Methods A meta‐analysis of meniscal repair failure (defined as persistent symptoms, lack of healing on magnetic resonance imaging or revision surgery) and other clinical outcomes was performed following meniscal repair. Patients included had traumatic, nondegenerative meniscal tears, were skeletally mature, and had specific time‐points after surgery. Repairs included were performed either in isolation, or with concomitant ACL reconstruction. Because of the inherent heterogeneity of single‐arm meta‐analyses, pooled analyses were performed using a random‐effects model. Results Rates of all‐cause meniscal repair failure was pooled to be 12% at 0‐1 years (95% CI: .09‐.16), 15% at 2‐3 years (95% CI: .11‐.20), and 19% at 4‐6 years (95% CI: .13‐.24). Sensitivity analysis for studies performing meniscal repair entirely on patients with concomitant ACL reconstruction (ACLR) showed comparable rates of failure at similar time intervals. Development of osteoarthritis, in patients with knees previously free from articular pathologies, was 4% at 2‐3 years (95% CI: .02‐.07), and 10% at 4‐6 years (95% CI: .03‐.25). Conclusion Meniscus repair for traumatic injuries have an all‐cause failure rate that increases from 12% to 19% through a time period ranging from 1‐6 years following surgery. The failure rates were comparable for patients with meniscal repairs performed with concomitant ACLRs. Level of Evidence IV; Systematic Review of Level II‐IV Studies.
Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection
Sehgal, Kanika , Singh, Sumitabh , Grover, Madhusudan , Pardi, Darrell S. , Khanna, Sahil , Saha, Srishti

Mayo Clinic

Journal of Clinical Gastroenterology | May 28, 2021 | Volume: 56 | Issue: 2 | Pages: e84-e93

10.1097/mcg.0000000000001536 | PMID 34049374 Get It

Background: Postinfection irritable bowel syndrome (PI-IBS) affects ~14% patients after acute bacterial enterocolitis. Aim: The aim of this study was to conduct a systematic review and meta-analysis to find the prevalence of PI-IBS following Clostridioides difficile infection (CDI). Methods: We systematically searched Medline, Embase, and Web of Science from inception through January 20, 2020 for cohort studies assessing PI-IBS following CDI. Primary outcome was pooled prevalence calculated using inverse variance heterogeneity model [MetaXL (v. 5.3)]. A priori subgroup analyses were done [by irritable bowel syndrome (IBS) diagnostic criteria-Rome vs. others, time of IBS diagnosis-<6 or >6 mo, exclusion or inclusion of pre-existing IBS and CDI treatment-antibiotic with fecal microbiota transplantation vs. antibiotic only]. Heterogeneity was considered substantial if I 2 >50%. Results: From 2007 to 2019, 15 studies were included (10 prospective, 5 retrospective; 9 full-text, 6 abstracts). Data from 1218 patients were included in the quantitative analysis. Risk of bias was low in 7, medium in 4 and high in 4 studies. Pooled prevalence of PI-IBS was 21.1% (95% confidence interval, 8.2%-35.7%), I 2 =96%. Common PI-IBS subtypes were diarrhea-predominant in 46.3% (50) patients, and mixed in 33.3% (36) patients. Subgroup analyses by IBS diagnostic criteria, time of IBS diagnosis or CDI treatment did not significantly change the primary outcome (all P >0.05), nor decrease heterogeneity. Funnel plot analysis revealed publication bias. Conclusions: Over 20% of patients develop PI-IBS after CDI. Factors such as diagnostic criteria for IBS and CDI treatment did not affect prevalence, though small numbers limit the confidence in these conclusions. Larger, well conducted studies are needed to study PI-IBS in CDI.
Good Recovery Is Possible in Young Patients With Posttraumatic Coma and Brainstem Microbleeds
Rabinstein, Alejandro A.

Mayo Clinic

Neurology | May 28, 2021 | Volume: 97 | Issue: 2 | Pages: 53-54

10.1212/wnl.0000000000012197 | PMID 34050008 Get It

Opportunistic Salpingectomy Versus Traditional Partial Salpingectomy at the Time of Cesarean Delivery: A Randomized Controlled Trial
Raju, Rubin , Thompson, Angela C., Dow, Margaret L. , Traynor, Kyle D., Elliott, Laura L., Wetzstein, Marnie M. , Hathcock, Matthew , Torbenson, Vanessa E. , Rivera‐Chiauzzi, Enid Y.

Mayo Clinic

No container title available | May 28, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-537534/v1 Get It

Abstract BACKGROUND: It is estimated that one third of women in the United States opt for permanent tubal sterilization at the time of cesarean delivery. Evidence suggests that ovarian cancer begins in the fallopian tubes. Ovarian cancer has the highest mortality of all gynecologic malignancies. There is no proven effective screening for ovarian cancer. In view of this, the Royal College of Obstetricians & Gynecologists and the American College of Obstetricians and Gynecologists recommend considering counseling patients about prophylactic salpingectomy as an effective method of sterilization. There are limited well designed clinical trials that compare the safety and feasibility of total salpingectomy to that of traditional partial salpingectomy for tubal sterilization at the time of cesarean delivery. METHODS: We conducted a non-inferiority randomized controlled trial at the Mayo Clinic, Rochester, Minnesota. Women age 21 years and older who were undergoing cesarean delivery and desired concomitant sterilization were enrolled between May 17, 2017 and July 16, 2018. Stratified randomization was performed based on number of previous cesarean deliveries and their Basal Metabolic Index, into a bilateral total salpingectomy group and bilateral partial salpingectomy group. All salpingectomies were performed using clamps and suture. The primary outcome was to compare the mean peri-operative hemoglobin change for both groups. Secondary objectives included sterilization completion time, postoperative length of stay, estimated blood loss, postoperative pain and adverse events. RESULTS: Of the 111 women screened, 40 were enrolled and randomized. Of these, 38 underwent the assigned procedure (18 BTS, 20 BPS). There were no demographic differences between groups. No difference in Mean ±SD hemoglobin drop between groups (1.4±0.7 g/dl for the BTS group and 1.8±1.0 g/dl for the BPS group, p=0.08). Mean time to completion of sterilization procedure was significantly longer in the BTS group (16.3±5.6 minutes for the BTS group vs 5.1±1.6 minutes for the BPS group, p < .01). No significant differences for other outcome measures.CONCLUSIONS: Bilateral total salpingectomy at the time of cesarean delivery does not increase the risk for blood loss and has similar peri-operative outcomes, with a small increase in operative time when compared to traditional bilateral partial salpingectomy. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03135431, 27/04/2017